Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward Keystone

Showing results (41-50 of 86) with videos related to

Pageof 9
Sort By:
RMD Open|January 21, 2020
Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritisJosef S Smolen, Jung-Yoon Choe, Michael E Weinblatt, et al.
Arthritis and Rheumatism|November 1, 2008
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyEdward Keystone, Désireé van der Heijde, David Mason, et al.
Journal of the American Academy of Dermatology|April 26, 2006
A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosisRobert M Knobler, Lars E French, Youn Kim, et al.
Seminars in Arthritis and Rheumatism|September 5, 2018
A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis populationAlan J Kivitz, Stanley Cohen, Edward Keystone, et al.
Arthritis and Rheumatism|February 5, 2005
SLC22A4 polymorphisms implicated in rheumatoid arthritis and Crohn's disease are not associated with rheumatoid arthritis in a Canadian Caucasian populationBill Newman, Richard F Wintle, Mark van Oene, et al.
Arthritis Care & Research|November 11, 2017
Early Rheumatoid Arthritis Presentation, Treatment, and Outcomes in Aboriginal Patients in Canada: A Canadian Early Arthritis Cohort Study AnalysisSujay Nagaraj, Cheryl Barnabe, Orit Schieir, et al.
Journal of Clinical Pharmacology|October 17, 2024
Pharmacokinetics and Safety of Intravenous Candidate Biosimilar CT-P47 and Reference Tocilizumab: A Randomized, Double-Blind, Phase 1 StudyMiwa Haranaka, Takashi Eto, Takanori Tanaka, et al.
Annals of the Rheumatic Diseases|May 7, 2010
Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD studyEdward Keystone, Mark C Genovese, Lars Klareskog, et al.
Rheumatology Advances in Practice|May 14, 2023
Impact of the COVID-19 pandemic on patients with rheumatoid arthritis: data from the Ontario Best Practices Research Initiative (OBRI)Matthew Wong-Pack, Elliot Hepworth, Mohammad Movahedi, et al.
Clinical and Experimental Rheumatology|March 25, 2017
Thresholds for the 28-joint disease activity score (DAS28) using C-reactive protein are lower compared to DAS28 using erythrocyte sedimentation rate in early rheumatoid arthritisBindee Kuriya, Orit Schieir, Daming Lin, et al.
Pageof 9

Showing results (41-50 of 86) with videos related to

Sort By:
Pageof 9
RMD Open|January 21, 2020
Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritisJosef S Smolen, Jung-Yoon Choe, Michael E Weinblatt, et al.
Arthritis and Rheumatism|November 1, 2008
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyEdward Keystone, Désireé van der Heijde, David Mason, et al.
Journal of the American Academy of Dermatology|April 26, 2006
A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosisRobert M Knobler, Lars E French, Youn Kim, et al.
Seminars in Arthritis and Rheumatism|September 5, 2018
A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis populationAlan J Kivitz, Stanley Cohen, Edward Keystone, et al.
Arthritis and Rheumatism|February 5, 2005
SLC22A4 polymorphisms implicated in rheumatoid arthritis and Crohn's disease are not associated with rheumatoid arthritis in a Canadian Caucasian populationBill Newman, Richard F Wintle, Mark van Oene, et al.
Arthritis Care & Research|November 11, 2017
Early Rheumatoid Arthritis Presentation, Treatment, and Outcomes in Aboriginal Patients in Canada: A Canadian Early Arthritis Cohort Study AnalysisSujay Nagaraj, Cheryl Barnabe, Orit Schieir, et al.
Journal of Clinical Pharmacology|October 17, 2024
Pharmacokinetics and Safety of Intravenous Candidate Biosimilar CT-P47 and Reference Tocilizumab: A Randomized, Double-Blind, Phase 1 StudyMiwa Haranaka, Takashi Eto, Takanori Tanaka, et al.
Annals of the Rheumatic Diseases|May 7, 2010
Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD studyEdward Keystone, Mark C Genovese, Lars Klareskog, et al.
Rheumatology Advances in Practice|May 14, 2023
Impact of the COVID-19 pandemic on patients with rheumatoid arthritis: data from the Ontario Best Practices Research Initiative (OBRI)Matthew Wong-Pack, Elliot Hepworth, Mohammad Movahedi, et al.
Clinical and Experimental Rheumatology|March 25, 2017
Thresholds for the 28-joint disease activity score (DAS28) using C-reactive protein are lower compared to DAS28 using erythrocyte sedimentation rate in early rheumatoid arthritisBindee Kuriya, Orit Schieir, Daming Lin, et al.
Pageof 9